Clinical Trials on Carcinoma, Non-Small-Cell Lung

Total 18425 results

National Cancer Institute (NCI)

Terminated

Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery

Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
Mohamed Abdel Bary Ahmed Ibrahim

Completed

Endobronchial Cryotherapy in Management of MEBO in Patients With Inoperable NSCLC

Non Small Cell Lung Cancer | Non-Small Cell Carcinoma of Lung, TNM Stage 4 | Bronchogenic Cancer
Stanford University
AstraZeneca

Recruiting

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage II

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
University of California, Davis
National Cancer Institute (NCI); Merck Sharp & Dohme LLC; Novartis

Active, not recruiting

Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations

KRAS Gene Mutation | Stage IV Non-Small Cell Lung Cancer AJCC v7 | Recurrent Non-Squamous Non-Small Cell Lung Carcinoma | Metastatic Non-Squamous Non-Small Cell Lung Carcinoma

United States
Hasselt University
Jessa Hospital; University Hospital, Ghent; University Ghent

Recruiting

Investigating the Feasibility of a Physical Activity (Tele)Coaching Intervention in Patients With Non-small Cell Lung Cancer: an Explorative Study (LUCA-coach)

Non-small Cell Lung Cancer | Non-small Cell Carcinoma

Belgium
University of Washington
National Cancer Institute (NCI)

Completed

FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging

Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7

United States
Roswell Park Cancer Institute

Completed

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | EGFR Gene Mutation

United States
University of California, San Francisco
AstraZeneca

Active, not recruiting

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung Cancer

United States
Sun Yat-sen University

Completed

Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Mersana Therapeutics

Completed

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

Small Cell Lung Cancer | Non-small Cell Lung Cancer

United States
Neal Ready
Merck Sharp & Dohme LLC

Active, not recruiting

Neoadjuvant Pembrolizumab (TOP 1501)

Non-small Cell Lung Carcinoma

United States
Eli Lilly and Company

Completed

A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

Belgium, France, Germany, Portugal, Spain, Sweden, Italy, United States, Canada, Netherlands, Argentina, Australia, Austria, Brazil, Denmark, Finland, Greece, Hungary, India, Israel, Korea, Republic of, Mexico, Poland, Puerto Rico, Taiwan, Turk... and more
Institut de Cancérologie de la Loire

Completed

Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer

Non-Small-Cell Lung Carcinoma

France
Bristol-Myers Squibb

Completed

Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response

Non-Small-Cell Lung Carcinoma

Japan
AstraZeneca

Terminated

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

Non Small Cell Lung Carcinoma

Italy
Providence Health & Services
Sanofi; Providence Cancer Center, Earle A. Chiles Research Institute

Terminated

Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer

Non-small-Cell Lung Carcinoma

United States
AZ-VUB
Sanofi

Unknown

Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Carcinoma

Belgium
Latin American Cooperative Oncology Group
Conselho Nacional de Desenvolvimento Científico e Tecnológico; Instituto do...

Completed

Use of [18]F-FDG on PET/CT as an Alternative Non-invasive Method for Staging of Lung Cancer

Non-small Cell Lung Carcinoma

Brazil
Spectrum Pharmaceuticals, Inc

Withdrawn

A Study to Assess the Safety and Preliminary Efficacy of PT-523 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-Small-Cell Lung Carcinoma

United States, Russian Federation
Ontario Clinical Oncology Group (OCOG)
Ontario Ministry of Health and Long Term Care

Completed

Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer (PET START Trial)

Non-Small-Cell Lung Carcinoma

Canada
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

Philippines, Thailand, France, Korea, Republic of, Hong Kong, United States, Turkey, Malaysia, Taiwan, Brazil, Serbia, Greece, Slovakia, Peru, South Africa, Mexico, Vietnam, Bangladesh
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Singapore, Hong Kong, Canada
National Cancer Institute (NCI)

Completed

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer

United States
National Cancer Institute (NCI)

Completed

Prospective Analysis of Genotypes in Adults Undergoing Therapy for Lung Cancer

Carcinoma, Non-Small Cell Lung | Carcinoma, Small-Cell Lung

United States
UNICANCER
National Cancer Institute, France

Recruiting

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG)

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Non-Small Cell Carcinoma of Lung, TNM Stage 4

France, Monaco
Peking Union Medical College Hospital

Recruiting

A Real-world Study of Durvalumab for Lung Cancer in China

Non Small Cell Lung Cancer Stage III | Small-Cell Lung Cancer

China
University of Maryland, Baltimore
University of Maryland, College Park

Terminated

Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies (0805GCC)

Non-Small Cell Lung Cancer, Small Cell Lung Cancer | Platinum Responsive Malignancies

United States
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL)

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States
The First Affiliated Hospital of Xinxiang Medical...

Recruiting

Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients (AP)

Lung Cancer | Non Small Cell Lung Cancer | Lung Carcinoma | Non-small Cell Carcinoma | Lung Neoplasm

China
Centre René Gauducheau

Completed

TF2- Small Cell Lung Cancer Radio Immunotherapy

Small Cell Lung Cancer | CEA-expressing Non Small Cell Lung Carcinoma (NSCLC)

France
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Withdrawn

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Adult Solid Neoplasm

United States
National Cancer Institute (NCI)

Recruiting

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Stage IV Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Recurrent Lung Non-Squamous Non-Small Cell Carcinoma

United States
Washington University School of Medicine
Polaris Group

Recruiting

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Small Cell Lung Carcinoma | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Small-cell Lung Cancer

United States
National Cancer Institute (NCI)

Not yet recruiting

Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

Stage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung Cancer

Canada
NovaRx Corporation

Completed

Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP)

Lung Neoplasm | Carcinoma Non-small Cell Lung Cancer Stage IIIA | Carcinoma Non-small Cell Lung Cancer Stage IIIB | Carcinoma Non-small Cell Lung Cancer Stage IV

United States, Hungary, United Kingdom, Netherlands, Canada, India, Poland, Serbia
Xcovery Holding Company, LLC

Not yet recruiting

BPI-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Carcinoma
European Lung Cancer Working Party

Completed

Biological Factors Predicting Response to Chemotherapy in Advanced Non Small Cell Lung Cancer

Non Small Cell Lung Carcinoma

Belgium
Maastricht Radiation Oncology

Completed

Safety Study of Individualised Radiation Dose Determination for Lung Cancer Patients.

Non-Small-Cell Lung Carcinoma

Netherlands
Yonsei University

Completed

Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy

Non-small Cell Lung Carcinoma

Korea, Republic of
Sidney Kimmel Cancer Center at Thomas Jefferson...
AstraZeneca

Completed

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma (NSCLC)

United States
AstraZeneca

Completed

Epidemiological Study to Describe Non Small Cell Lung Cancer Clinical Management Patterns in MENA. Lung-EPICLIN/ Gulf (Lung-EPICLIN/G)

Non Small Cells Lung Cancer

Qatar, Bahrain, United Arab Emirates
AstraZeneca

Active, not recruiting

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)

Non-Small-Cell Lung Carcinoma

France, Spain, Thailand, Belgium, Korea, Republic of, Netherlands, United States, Brazil, Japan, China, Malaysia, Taiwan, Australia, Denmark
Duke University

Completed

Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer (TOP 1502)

Non-small Cell Lung Carcinoma

United States
Transgene

Terminated

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer (TIME)

Non-Small-Cell Lung Carcinoma

United States, France, Hungary, United Kingdom, Spain, Israel, Belgium, Germany, Poland, Italy
Novartis Pharmaceuticals

Completed

Study Investigating the Effect of Everolimus Monotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-small-cell Lung Carcinoma

United States
University of Cologne

Completed

Molecular Imaging With Erlotinib and Bevacizumab (MIMEB)

Non-Small-Cell Lung Carcinoma

Germany
Sanofi

Terminated

Safety Study of Docetaxel/Cisplatin Induction Therapy Followed by Concurrent Chemoradiotherapy or Concurrent Chemoradiotherapy Followed by Consolidation Docetaxel/Cisplatin in NSCLC Patients

Non-Small-Cell Lung Carcinoma

France
Maastricht Radiation Oncology
Pfizer

Completed

Phase II Study of Celecoxib and Concurrent Radiotherapy in Stage II-III NSCLC

Non Small Cell Lung Carcinoma

Netherlands
Maastricht Radiation Oncology

Completed

HI-CHART:Feasibility of High-Dose Accelerated Conformal Radiotherapy

Non-Small-Cell Lung Carcinoma

Netherlands

Clinical Trials on Carcinoma, Non-Small-Cell Lung

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations